WIKIMEDIA, RUSSAVIAPeople in the United Kingdom with mitochondrial disorders who want to use a novel in vitro fertilization (IVF) technique to make offspring with a reduced chance of inheriting their diseases may not have to wait too much longer, according to a report released Tuesday (June 3) by the U.K.’s Human Fertilization and Embryology Authority (HFEA). The experimental procedures—so-called mitochondrial replacement techniques termed maternal spindle transfer (MSF) and pronuclear transfer (PT)—are “not unsafe” for use on a “specific and defined group of patients,” according to the report. But the HFEA also said that additional testing must be carried out before the procedures can make it into the clinic. “The review process has assembled an evidence base on the safety and efficacy of these two mitochondrial replacement techniques which stands comparison with anything published in the U.K. or abroad,” said Sally Cheshire, HFEA chair, in a statement. “The science is complex, but the aim is simple: to enable mothers to not pass on to their children a range of serious, and sometimes fatal, inherited conditions.”
Both mitochondrial replacement methods use oocytes from two women and sperm from one man. In MSF, nuclei from the egg cells with malfunctioning mitochondria donated by the mother are transferred to donor oocytes with normal mitochondria before that donor egg is fertilized by sperm. In PT, the two oocytes—one from the mother and one from a donor—are fertilized and the nucleus from the zygote with malfunctioning mitochondria is transferred into the donor embryo.
Robin Lovell-Badge, a researcher with the U.K.’s Medical Research Council and a member of the HFEA panel that issued the report, told BBC News that the continued scientific testing of the mitochondrial replacement techniques, such as studies that determine the effects of a single embryo having a mix of mitochondrial DNA, shouldn’t ...
